Perampanel is under clinical development by Eisai and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Perampanel’s likelihood of approval (LoA) and phase transition for Amyotrophic Lateral Sclerosis took place on 18 Jan 2021, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Perampanel Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Perampanel overview

Perampanel (Fycompa) belongs to the class of antiepileptic agents. It is formulated as film coated tablets, tablets, granules and suspension for oral route of administration. Fycompa is indicated as adjunctive therapy for the treatment of partial-onset seizures with or without secondarily generalized seizures in patients with epilepsy 12 years of age and older, as adjunctive therapy for the treatment of primary generalized tonic-clonic seizures in patients  with epilepsy 12 years of age and older. It is also indicated as monotherapy use for the treatment of partial-onset seizures (with or without secondarily generalized seizures) in patients with epilepsy 12 years of age and older, and also indicated for the treatment of partial onset seizures(POS), with or without secondarily generalized seizures to include patients 4 to 12 years. Fycompa is also indicated for the treatment of partial-onset seizures in pediatric patients aged 4 years and older.

The drug candidate is under development for the treatment of amyotrophic lateral sclerosis, partial-onset seizures, pediatric partial-onset seizures. Perampanel was also under development for the treatment of diabetic neuropathy, Parkinson's disease, migraine and neuropathic pain and epilepsy.

It was under development for the treatment of Lennox-gastaut syndrome.

Eisai overview

Eisai is a pharmaceutical company that discovers, develops, manufactures and markets pharmaceuticals, including prescription medicines, OTC drugs and generics. The company’s franchise areas in research include neurology and oncology. Eisai’s major products include Pariet/AcipHex, a proton pump inhibitor; Aricept, an anti-Alzheimer agent; perampanel, Halaven, an anti-cancer agent; Fycompa tablets for the treatment of epilepsy and peripheral neuropathy. Eisai has production plants in Japan, the UK, China and India and laboratories in Japan, the US and the UK; operations in the Americas, Asia and Latin America, EMEA and Oceania with overseas sales offices in the US, Germany, France, China and South Korea. Eisai is headquartered in Tokyo, Japan.

Quick View Perampanel LOA Data

Report Segments
  • Innovator (NME)
Drug Name
  • Perampanel
Administration Pathway
  • Intravenous
  • Oral
Therapeutic Areas
  • Central Nervous System
  • Metabolic Disorders
Key Developers
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.